GoAI
Get started
China SXT Pharmaceuticals, Inc. logo

China SXT Pharmaceuticals, Inc.

SXTC

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$4.10

+$0.47 · +12.95%

Aug 21, 4:00 PM ET

Pre-market

$3.88

−$0.22 · -5.37%

Aug 24, 8:05 AM ET

SXTC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

62

Undervalued

Momentum

35

Weakening

Sentiment

57

Mixed

Risk resilience

21

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Feng Zhou
Listed since
Jan 4, 2019
Employees
56

Market position

Day range

Current $4.10

52-week range

Current $4.10

Open
$3.95
Previous close
$3.63
Volume
3M
4.46× average
Average volume
672.48K
Average daily volume
Market cap
2.19M USD
Beta
1.9
Market reference 1
50-day average
$110.27
-96.28% below average
200-day average
$4,147.43
-99.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
64.29M USD
P/E (TTM)
-0.48×
P/B (TTM)
0.08×
P/S (TTM)
0.86×
EV / EBITDA
-9.21×
Earnings yield
-6.79%
Free cash flow yield
-4.40%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
44.37%
Operating margin
-336.53%
Net margin
-290.71%
Return on equity
-20.89%
Return on assets
-17.85%
Return on invested capital
-23.11%

Financial health

Debt / equity
0.04×
Current ratio
7.93×
Altman Z-score
-0.81
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends119%-166%-450%-735%Gross margin, FY2022: 48.10%Gross margin, FY2023: 21.62%Gross margin, FY2024: 28.73%Gross margin, FY2025: 21.11%Gross margin, FY2026: 17.09%Operating margin, FY2022: -199.43%Operating margin, FY2023: -284.40%Operating margin, FY2024: -130.42%Operating margin, FY2025: -153.97%Operating margin, FY2026: -664.06%Net margin, FY2022: -220.43%Net margin, FY2023: -301.00%Net margin, FY2024: -160.67%Net margin, FY2025: -189.77%Net margin, FY2026: -578.49%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 48.10%. Gross margin FY2023 21.62%. Gross margin FY2024 28.73%. Gross margin FY2025 21.11%. Gross margin FY2026 17.09%. Operating margin FY2022 -199.43%. Operating margin FY2023 -284.40%. Operating margin FY2024 -130.42%. Operating margin FY2025 -153.97%. Operating margin FY2026 -664.06%. Net margin FY2022 -220.43%. Net margin FY2023 -301.00%. Net margin FY2024 -160.67%. Net margin FY2025 -189.77%. Net margin FY2026 -578.49%.

Income trends

Revenue

1.07M USD-38.39%

Operating income

−7.12M USD-165.73%

Net income

−6.21M USD-87.83%
Income trends across reported periods3.57M USD−315.28K USD−4.21M USD−8.1M USDRevenue, FY2022: 2.6M USDRevenue, FY2023: 1.97M USDRevenue, FY2024: 1.93M USDRevenue, FY2025: 1.74M USDRevenue, FY2026: 1.07M USDOperating income, FY2022: −5.19M USDOperating income, FY2023: −5.61M USDOperating income, FY2024: −2.52M USDOperating income, FY2025: −2.68M USDOperating income, FY2026: −7.12M USDNet income, FY2022: −5.74M USDNet income, FY2023: −5.93M USDNet income, FY2024: −3.1M USDNet income, FY2025: −3.3M USDNet income, FY2026: −6.21M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 2.6M USD. Revenue FY2023 1.97M USD. Revenue FY2024 1.93M USD. Revenue FY2025 1.74M USD. Revenue FY2026 1.07M USD. Operating income FY2022 −5.19M USD. Operating income FY2023 −5.61M USD. Operating income FY2024 −2.52M USD. Operating income FY2025 −2.68M USD. Operating income FY2026 −7.12M USD. Net income FY2022 −5.74M USD. Net income FY2023 −5.93M USD. Net income FY2024 −3.1M USD. Net income FY2025 −3.3M USD. Net income FY2026 −6.21M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue1.07M USD1.74M USD1.93M USD1.97M USD2.6M USD
Cost of goods sold889.35K USD1.37M USD1.37M USD1.55M USD1.35M USD
Gross profit183.28K USD367.43K USD553.97K USD426.27K USD1.25M USD
Research and development178.77K USD191.39K USD184.19K USD——
Selling, general, and administrative7.13M USD3.05M USD3.07M USD6.03M USD6.44M USD
Operating expenses7.31M USD3.05M USD3.07M USD6.03M USD6.44M USD
Interest expense62.97K USD648.22K USD544.28K USD476.78K USD36.7K USD
Depreciation and amortization143.22K USD82.3K USD203.25K USD250.16K USD320.01K USD
Operating income−7.12M USD−2.68M USD−2.52M USD−5.61M USD−5.19M USD
Net income−6.21M USD−3.3M USD−3.1M USD−5.93M USD−5.74M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-9.13
FY2026
Latest fiscal-year revenue
1.07M USD
FY2026 · -38.39% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend9.87-43.87-97.61-151.36FY22FY23FY24FY25FY26

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend2.76M2.14M1.53M919.67KFY22FY23FY24FY25FY26

SXTC news

globenewswire.com

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

TAIZHOU, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the “Company”), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per…

Read source
globenewswire.com

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the…

Read source
globenewswire.com

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the…

Read source
globenewswire.com

China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

TAIZHOU, China, July 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive securities purchase agreement with certain…

Read source
defenseworld.net

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 37.4% in June

China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC - Get Free Report) was the recipient of a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 45,019 shares, a…

Read source

Corporate actions

Corporate action history

Stock split

Effective Aug 10, 2026

1:80

Stock split

Effective Feb 3, 2026

1:150

Stock split

Effective Feb 25, 2025

1:8

Stock split

Effective Oct 5, 2023

1:25

Stock split

Effective May 19, 2022

1:20

Stock split

Effective Feb 22, 2021

1:4

SXTC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research SXTC

research.disclaimer